Dana-Farber Cancer Institute agreed on December 16, 2025, to pay $15 million to the United States to settle allegations that its researchers used manipulated and duplicated images in work funded by National Institutes of Health grants. The Dana-Farber $15 million settlement resolves a False Claims Act lawsuit brought by a Welsh molecular biologist, Sholto David, who had publicly flagged image problems in dozens of the institute’s cancer biology papers in January 2024. Dana-Farber acknowledged specific misconduct tied to 14 publications and six NIH grants but did not admit intentional fraud.1U.S. Department of Justice announcement, December 16, 2025
What Dana-Farber Admitted
The institute acknowledged that its scientists used funds from six NIH grants for research that produced 14 publications containing misrepresented or duplicated images and data. The manipulation took several forms: reusing images to represent different experimental conditions, duplicating images to stand in for different mice or timepoints, and rotating, magnifying, or stretching images to misrepresent results. Dana-Farber also admitted that it spent grant funds on expenses the government deemed “unallowable,” and that the certifications submitted with those grants amounted to false claims to the NIH.
The settlement did not name the researchers directly, referring to them as “Researcher 1” and “Researcher 2.” According to STAT News and the Retraction Watch database, Researcher 1 is Kenneth Anderson, a hematologist and director of Dana-Farber’s Jerome Lipper Multiple Myeloma Center. Anderson was the senior author on 12 of the 14 papers linked to the first group of grants, and the settlement stated that he failed to exercise sufficient oversight over the lab members who prepared the publications and conducted the underlying research.
Researcher 2 was identified as Ruben Carrasco, a cancer researcher affiliated with Dana-Farber and Brigham and Women’s Hospital. The settlement stated that Carrasco received four NIH grants after submitting applications that cited a 2015 Nature Medicine paper he had authored, “The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells,” without disclosing that the paper contained misrepresented or duplicated images and data. That paper was not retracted; it received a formal author correction from Nature Medicine in July 2024 addressing image reuses and figure discrepancies.
How the $15 Million Breaks Down
Dana-Farber will pay the $15 million plus interest of 4.375% per year accruing from August 27, 2025. More than $8.5 million of the total is designated as restitution to the United States. Sholto David, as the whistleblower who initiated the case, will receive 17.5% of the settlement, or $2.625 million. His attorneys were paid $328,498.53 in fees.
The settlement is a resolution of allegations, not an admission of intentional fraud. Dana-Farber received cooperation credit under Department of Justice guidelines for voluntarily disclosing additional instances of research misconduct beyond what David had identified, producing documents without a subpoena, and implementing remedial measures. That cooperation likely held the amount well below the treble damages the False Claims Act permits.
How the Case Started
Sholto David was a 32-year-old unemployed scientist in Pontypridd, Wales, when he published a blog post on January 2, 2024, titled “Dana-Farberications at Harvard University” on the independent research integrity site For Better Science. He alleged that Dana-Farber researchers had manipulated images across dozens of cancer biology papers published between 1999 and 2017, describing copied-and-pasted bands in western blots, duplicated flow cytometry plots, and other signs of tampering. He holds a doctorate in cell and molecular biology from Newcastle University and had used PubPeer and an AI tool called ImageTwin to identify potentially duplicated images.
The post named four senior Dana-Farber figures: CEO Laurie Glimcher, COO William Hahn, senior researcher Irene Ghobrial, and hematologist Kenneth Anderson. Dana-Farber launched an internal review, and within weeks announced plans to request retractions of six studies and corrections to 31 others.
On April 22, 2024, David filed a lawsuit against Dana-Farber in the U.S. District Court for the District of Massachusetts under the qui tam provisions of the False Claims Act, which let private citizens sue on behalf of the federal government. The complaint, U.S. ex rel. Sholto David v. Dana-Farber Cancer Institute, Inc. (No. 24-cv-11059), originally cited 95 studies that David said reflected a “pattern of fraud.” The case remained sealed while the Justice Department investigated and reached resolution in about 20 months, unusually fast for a False Claims Act matter, which often takes at least three years.
Dana-Farber’s Response
Benjamin Ebert, president and CEO of Dana-Farber, said in a statement that “scientific errors do not meet the high standards that Dana-Farber expects from its researchers, and we act quickly and proactively to address them when they occur.” The institute said it had “cooperated fully” with the Justice Department and the U.S. Attorney’s Office and remained “committed to research integrity.” Ebert said Dana-Farber had begun developing initiatives to strengthen research integrity practices and improve what he called “data hygiene” even before the federal investigation.
Dana-Farber did not publicly identify the specific remedial measures it implemented, and the settlement did not detail them. The institute declined to comment on the employment status of any individual researchers, citing federal regulations and institutional policy.
The settlement focused narrowly on the grants linked to Anderson and Carrasco and did not address the work of Glimcher, Hahn, or Ghobrial. As of early 2024, Ghobrial had said she was aware of the allegations and had submitted corrections to journals. Hahn had submitted a corrected image for a 2011 paper. Glimcher did not publicly comment.
Anderson and the Retracted Papers
Kenneth Anderson is a professor of medicine at Harvard Medical School and one of the most prominent researchers in multiple myeloma. According to NBC News, Anderson was the senior author on six of the seven papers Dana-Farber ultimately retracted, in journals including Cancer Research and the Journal of Immunology. The Retraction Watch database lists Anderson as having 10 retractions dating back to 2008. Anderson agreed to the retractions of the papers he authored, according to Dana-Farber. The institute declined to share details of its internal review or any personnel actions, and the settlement did not prescribe consequences for individual researchers.
How This Compares to Other Research Fraud Settlements
The Dana-Farber payment is significant but not the largest of its kind. Duke University agreed in 2019 to pay $112.5 million to settle False Claims Act allegations that a researcher in its pulmonary division, Erin Potts-Kant, had systematically fabricated data on mouse lung function. The fraud tainted roughly $200 million in federal grants submitted between 2006 and 2018, led to 17 retractions, and affected 38 scholarly articles that had been cited in more than 400 other publications. The Duke whistleblower, former lab analyst Joseph Thomas, received $33.75 million.
Two smaller settlements landed in 2025. Northwestern University agreed in November 2025 to pay approximately $2.3 million after a researcher falsified data associated with NIH-funded grants totaling about $5 million; Northwestern self-disclosed the misconduct to the HHS Office of Inspector General. And in January 2025, the biotech company Athira Pharma paid roughly $4 million to settle allegations that it failed to report research misconduct to the NIH and the Office of Research Integrity in grant applications and progress reports.
For David, the settlement produced one of the largest payouts ever received by an individual science integrity whistleblower under the False Claims Act, validating the bet he made when he spent years of savings scrutinizing published science from a home office in Wales.